<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00074321</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-01444</org_study_id>
    <secondary_id>MC0311</secondary_id>
    <secondary_id>NCI-6240</secondary_id>
    <secondary_id>CDR0000344367</secondary_id>
    <secondary_id>MAYO-MC0311</secondary_id>
    <nct_id>NCT00074321</nct_id>
  </id_info>
  <brief_title>Irinotecan, Oxaliplatin, and Capecitabine in Treating Patients With Unresectable Solid Tumors</brief_title>
  <official_title>A Phase I And Pharmacogenetic Study Of CPT-11, Oxaliplatin, And Capecitabine In Patients With Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Drugs used in chemotherapy, such as irinotecan, oxaliplatin, and capecitabine, work in&#xD;
      different ways to stop tumor cells from dividing so they stop growing or die. Combining more&#xD;
      than one chemotherapy drug may kill more tumor cells. This phase I trial is studying the side&#xD;
      effects and best dose of irinotecan, oxaliplatin, and capecitabine in treating patients with&#xD;
      unresectable solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. To define the maximally tolerated dose of the combination of CPT-11 (irinotecan&#xD;
      hydrochloride), oxaliplatin, and capecitabine in three different populations, based on UDP&#xD;
      glucuronosyltransferase 1 family, polypeptide A1 (UGT1A1) genotype (6/6, 6/7, and 7/7).&#xD;
&#xD;
      II. To identify any activity of this treatment combination in patients with metastatic&#xD;
      cancer.&#xD;
&#xD;
      III. To examine the differences in the toxicity profile, especially pertaining to hematologic&#xD;
      and gastrointestinal (GI), and the maximally tolerated dose of the combination of CPT-11,&#xD;
      oxaliplatin and capecitabine with respect to the UGT1A1 haplotypes.&#xD;
&#xD;
      IV. Examine the effect of the UGT1A1 genotype on the pharmacokinetics of CPT-11 and its&#xD;
      metabolites.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study. Patients are stratified according to UGT1A1&#xD;
      genotype (6/6 vs 6/7 [closed to accrual as of 8/24/06] vs 7/7).&#xD;
&#xD;
      Patients receive irinotecan hydrochloride intravenously (IV) over 90 minutes and oxaliplatin&#xD;
      IV over 2 hours on day 1 and capecitabine orally (PO) twice daily (QD) on days 2-15. Courses&#xD;
      repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of irinotecan hydrochloride, oxaliplatin,&#xD;
      and capecitabine until the maximum tolerated dose (MTD) is determined. The MTD is defined as&#xD;
      the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.&#xD;
      Once the MTD is determined, an additional 6-10 patients (for a total of 12 patients) receive&#xD;
      treatment at that dose.&#xD;
&#xD;
      After completion of study treatment, patients are followed up at 3 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 54-84 patients (12-22 for stratum I, 18-28 for stratum II&#xD;
      [closed to accrual as of 8/24/06], and 24-34 for stratum III) will be accrued for this study&#xD;
      within approximately 4.4 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2003</start_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MTD defined as one dose level below the lowest dose that induces dose-limiting toxicity in at least one-third of patients (at least 2 of a maximum of 6 new patients) assessed using NCI CTCAE v3.0</measure>
    <time_frame>3 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of UTG1A1*28 polymorphism</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>The overall incidence of UTG1A1*28 polymorphism will be estimated and summarized in this patient population. In addition, the incidence of this polymorphism will be explored in relation to tumor type.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events profile assessed using NCI CTCAE v3.0</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>The number and severity of all adverse events (overall, by dose level, and by tumor group) will be tabulated and summarized for the three patient groups. The grade 3+ adverse events will also be described and summarized in a similar fashion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity profile assessed using NCI CTCAE v3.0</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>Overall toxicity incidence as well as toxicity profiles by dose level, patient and tumor site will be explored and summarized in each of the two groups. Frequency distributions, graphical techniques and other descriptive measures will form the basis of these analyses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response profile using RECIST criteria</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>Responses will be summarized by simple descriptive summary statistics delineating complete and partial responses as well as table and progressive disease in the two patient populations (overall and by tumor group).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time until any treatment related toxicity</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>Will be summarized descriptively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time until treatment related grade 3+ toxicity</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>Will be summarized descriptively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time until hematologic nadirs (WBC, ANC, platelets)</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>Will be summarized descriptively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>Will be summarized descriptively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to treatment failure</measure>
    <time_frame>From registration to documentation of progression, unacceptable toxicity, or refusal to continue participation by the patient, assessed up to 3 months</time_frame>
    <description>Will be summarized descriptively.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive irinotecan hydrochloride IV over 90 minutes and oxaliplatin IV over 2 hours on day 1 and capecitabine PO QD on days 2-15. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>Campto</other_name>
    <other_name>Camptosar</other_name>
    <other_name>CPT-11</other_name>
    <other_name>irinotecan</other_name>
    <other_name>U-101440E</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>1-OHP</other_name>
    <other_name>Dacotin</other_name>
    <other_name>Dacplat</other_name>
    <other_name>Eloxatin</other_name>
    <other_name>L-OHP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>CAPE</other_name>
    <other_name>Ro 09-1978/000</other_name>
    <other_name>Xeloda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed solid tumor for which there is no known standard therapy that&#xD;
             is potentially curative or capable of extending life expectancy&#xD;
&#xD;
               -  Unresectable disease&#xD;
&#xD;
          -  Willing to provide biologic specimens to determine UGT1A1 genotype&#xD;
&#xD;
          -  No CNS metastases&#xD;
&#xD;
               -  Prior CNS metastases allowed provided patient was treated with surgery and/or&#xD;
                  radiotherapy and is stable for more than 8 weeks&#xD;
&#xD;
          -  Performance status - ECOG 0-2&#xD;
&#xD;
          -  At least 12 weeks&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 9.0 g/dL&#xD;
&#xD;
          -  Bilirubin no greater than upper limit of normal (ULN) for patients with 6/6 UGT1A1&#xD;
             genotype (1.5 times ULN for patients with 6/7 [closed to accrual as of 8/24/06] or 7/7&#xD;
             UGT1A1 genotype)&#xD;
&#xD;
          -  AST no greater than 3 times ULN (5 times ULN if there is liver involvement)&#xD;
&#xD;
          -  Creatinine no greater than 1.5 times ULN&#xD;
&#xD;
          -  No New York Heart Association class III or IV heart disease&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No prior allergy to platinum compounds, irinotecan, or to antiemetics or&#xD;
             antidiarrheals appropriate for administration with study therapy&#xD;
&#xD;
          -  No uncontrolled infection&#xD;
&#xD;
          -  No seizure disorder&#xD;
&#xD;
          -  No peripheral neuropathy grade 2 or greater&#xD;
&#xD;
          -  More than 4 weeks since prior biologic therapy&#xD;
&#xD;
          -  More than 4 weeks since prior immunotherapy&#xD;
&#xD;
          -  No concurrent immunotherapy&#xD;
&#xD;
          -  No concurrent prophylactic colony-stimulating factor therapy&#xD;
&#xD;
          -  More than 4 weeks since prior chemotherapy (6 weeks for mitomycin or nitrosoureas) and&#xD;
             recovered&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 4 weeks since prior radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy to more than 25% of the bone marrow&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No other concurrent investigational therapy&#xD;
&#xD;
          -  No concurrent sorivudine, brivudine, lamivudine, or stavudine&#xD;
&#xD;
          -  No concurrent enrollment in any other study involving a pharmacologic agent for&#xD;
             symptom control or therapeutic intent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew Goetz</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>December 10, 2003</study_first_submitted>
  <study_first_submitted_qc>December 10, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2003</study_first_posted>
  <last_update_submitted>June 5, 2013</last_update_submitted>
  <last_update_submitted_qc>June 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 6, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

